Valneva COVID-19 vaccine
This is an old revision of this page, as edited by Boghog (talk | contribs) at 07:45, 2 February 2021 (tweak cites). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Vaccine description | |
---|---|
Target | COVID-19 |
Vaccine type | Inactivated SARS-CoV-2 |
Clinical data | |
Other names | Valneva COVID-19 vaccine |
Routes of administration | Intramuscular |
ATC code |
|
VLA2001, also known as Valneva COVID-19 vaccine, is a COVID-19 vaccine candidate developed by Valneva SE.
Development
Valneva has developed a candidate inactivated whole virus vaccine against COVID-19, VLA2001[1] derived from its Ixiaro vaccine, which is undergoing a Phase 1/2 trial in the United Kingdom.[2][3] The Phase 1/2 trial has 150 participants testing three dose levels for safety, tolerability, and immunogenicity. The trial is expected to be complete by 15 February 2021, with full reporting completed by August 2021.[4]
Valneva has reached an agreement with the UK government to provide up to 100 million doses to be manufactured at its facility in Livingston, Scotland. The UK government has pre-ordered 60 million doses.[1][2] The trials are being supported by the UK National Institute for Health Research and four British universities.[4] Due to government support, Valneva will progress immediately into Phase 3 trials and develop production capacity before the full evaluation of the Phase 1/2 trial, rather than the traditional slower sequential approach which has lower financial risk.[5]
References
- ^ a b "VLA2001 COVID-19 Vaccine". Precision Vaccinations. 31 December 2020. Retrieved 11 January 2021.
- ^ a b "Covid: Clinical trials begin for Valneva vaccine". BBC News. 16 December 2020. Retrieved 11 January 2021.
- ^ "Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate". Valneva SE. 16 December 2020. Retrieved 18 December 2020.
- ^ a b Clinical trial number NCT04671017 for "Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults" at ClinicalTrials.gov
- ^ Nawrat A (6 August 2020). "Q&A with Valneva: UK Government scales up Covid-19 manufacturing". Pharmaceutical Technology. Retrieved 11 January 2021.
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
- Articles with short description
- Short description matches Wikidata
- Use dmy dates from January 2021
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine